

# Jing Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5273197/publications.pdf>

Version: 2024-02-01

43  
papers

476  
citations

759233

12  
h-index

839539

18  
g-index

44  
all docs

44  
docs citations

44  
times ranked

500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 237-245.	1.8	37
2	Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions. <i>Value in Health Regional Issues</i> , 2018, 15, 133-137.	1.2	36
3	Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. <i>European Journal of Health Economics</i> , 2022, 23, 607-615.	2.8	34
4	Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension. <i>Pharmacoeconomics</i> , 2021, 39, 521-535.	3.3	26
5	Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China. <i>Archives of Osteoporosis</i> , 2018, 13, 12.	2.4	25
6	The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study. <i>Value in Health</i> , 2017, 20, 412-419.	0.3	23
7	EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China. <i>Diabetes Therapy</i> , 2020, 11, 939-950.	2.5	18
8	Healthcare Resource Utilization and Direct Medical Costs for Patients With Osteoporotic Fractures in China. <i>Value in Health Regional Issues</i> , 2019, 18, 106-111.	1.2	16
9	Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study. <i>Pharmacoeconomics - Open</i> , 2021, 5, 101-109.	1.8	16
10	Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China. <i>Value in Health</i> , 2020, 23, 1391-1399.	0.3	15
11	Population Norms for SF-6Dv2 and EQ-5D-5L in China. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 573-585.	2.1	15
12	Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China. <i>Current Medical Research and Opinion</i> , 2018, 34, 1089-1098.	1.9	14
13	The Simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing. <i>Quality of Life Research</i> , 2020, 29, 1385-1391.	3.1	14
14	Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4386-4396.	2.4	12
15	Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6034.	2.6	12
16	Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. <i>PLoS ONE</i> , 2018, 13, e0191095.	2.5	11
17	Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China. <i>Clinical Therapeutics</i> , 2019, 41, 456-465.e2.	2.5	10
18	Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. <i>BMJ Open</i> , 2019, 9, e031186.	1.9	10

#	ARTICLE	IF	CITATIONS
19	Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 282.	1.7	10
20	Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type-2 Diabetes Mellitus: A Network Meta-analysis. <i>Advances in Therapy</i> , 2021, 38, 1470-1482.	2.9	10
21	Policy Updates on Access to and Affordability of Innovative Medicines in China. <i>Value in Health Regional Issues</i> , 2022, 30, 59-66.	1.2	10
22	Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals. <i>Pharmacoeconomics</i> , 2014, 32, 293-303.	3.3	9
23	Addressing methodological and ethical issues in practicing health economic evaluation in China. <i>Journal of Global Health</i> , 2020, 10, 020322.	2.7	9
24	Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type-1 and Patients with Type-2 Diabetes in China. <i>Diabetes Therapy</i> , 2021, 12, 3079-3092.	2.5	9
25	Financial toxicity of cancer in China. <i>Journal of Cancer Policy</i> , 2018, 15, 96-99.	1.4	8
26	Direct Medical Costs of Incident Complications in Patients Newly Diagnosed With Type 2 Diabetes in China. <i>Diabetes Therapy</i> , 2021, 12, 275-288.	2.5	8
27	Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	2.4	8
28	Increasing Anti-Infective Drug Expenditure in Tianjin, China: A Decomposition Analysis. <i>Value in Health Regional Issues</i> , 2013, 2, 37-42.	1.2	7
29	&lt;p&gt;Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China&lt;p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 2159-2169.	1.8	7
30	Incorporating future unrelated medical costs in cost-effectiveness analysis in China. <i>BMJ Global Health</i> , 2021, 6, e006655.	4.7	7
31	Association of severe hypoglycemia with all-cause mortality and complication risks among patients with type 2 diabetes mellitus in China. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108493.	2.8	6
32	Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 311-320.	1.4	5
33	Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China. <i>BMC Health Services Research</i> , 2015, 15, 149.	2.2	3
34	Discrete choice experiment with duration versus time trade-off: a comparison of testâ€“retest reliability of health utility elicitation approaches in SF-6Dv2 valuation. <i>Quality of Life Research</i> , 0, , .	3.1	3
35	International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 486-491.	0.5	2
36	Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6194.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Eliciting SF-6Dv2 health state utilities using an anchored best-worst scaling technique. <i>Social Science and Medicine</i> , 2021, 279, 114018.	3.8	2
38	Heterogeneity in Price Elasticity of Medicine Demand in China: Moderate Effect From Economic Incentive and Quality Difference. <i>Frontiers in Pharmacology</i> , 2021, 12, 688069.	3.5	2
39	Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 743-755.	2.1	2
40	Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population. <i>Haemophilia</i> , 2022, 28, 776-783.	2.1	2
41	China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population. <i>Pharmacoeconomics</i> , 2022, 40, 957-969.	3.3	1
42	Perioperative inhaled corticosteroids treatment is associated with decreased length-of-stay and direct medical costs in high-respiratory-risk surgeries. <i>Journal of Medical Economics</i> , 2020, 23, 280-286.	2.1	0
43	Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective. <i>BMC Ophthalmology</i> , 2021, 21, 229.	1.4	0